Document is current
Any future updates will be listed below
-
Authors
Corleis, Björn
Hoffmann, Donata https://orcid.org/0000-0003-4552-031X
Rauch, Susanne
Fricke, Charlie https://orcid.org/0000-0001-7493-6627
Roth, Nicole
Gergen, Janina
Kovacikova, Kristina https://orcid.org/0000-0002-6582-222X
Schlottau, Kore https://orcid.org/0000-0002-3999-0393
Halwe, Nico Joel https://orcid.org/0000-0002-7983-2808
Ulrich, Lorenz https://orcid.org/0000-0001-5004-806X
Schön, Jacob
Wernike, Kerstin https://orcid.org/0000-0001-8071-0827
Widera, Marek https://orcid.org/0000-0001-5417-9307
Ciesek, Sandra https://orcid.org/0000-0002-1802-7565
Mueller, Stefan O. https://orcid.org/0000-0001-6549-8936
Mettenleiter, Thomas C. https://orcid.org/0000-0002-8385-7899
Maione, Domenico https://orcid.org/0000-0002-8441-9241
Petsch, Benjamin
Beer, Martin https://orcid.org/0000-0002-0598-5254
Dorhoi, Anca https://orcid.org/0000-0003-1739-749X
- License Information
-
More Information
Article History
Received: 22 April 2022
Accepted: 15 January 2023
First Online: 13 February 2023
Competing interests
: B.C., B.P., M.B. and A.D. report institutional funding for the work. S.R., N.R., J.G., K.K., S.O.M. and B.P. are employees of CureVac SE, Tübingen, Germany, a publicly listed company developing mRNA-based vaccines and immunotherapeutics. Authors may hold shares in the company. S.R., B.P. and N.R. are inventors on several patents on mRNA vaccination and use thereof. D.M. holds shares in GSK. All other authors declare no conflicts of interest.
